Investors

Profile

Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of targeted small molecule drugs to treat patients afflicted with cancer. Seven Phase 3 or pivotal studies are already in progress, or are planned to begin, within the next year. These programs include the wholly-owned hematology drug, ARRY-520, for multiple myeloma and two partnered cancer drugs, selumetinib (AstraZeneca) and MEK162 (Novartis).

Array BioPharma
Fact Sheet

Array BioPharma
2013 Annual Report

Stock Quote & Chart

ARRY (Common Stock)
ExchangeNASDAQ (US Dollar)
Price$3.74
Change (%) Stock is Down 0.04 (1.06%)
Volume872,103
Data as of 08/22/14 4:00 p.m. ET
Minimum 20 minute delay
Refresh quote
 
Stock chart for: 03NA000000ARRY
Recent NewsMore >>

Upcoming Events

More >>
There are currently no events scheduled.
Primary IR Contacts
Michael Carruthers
Chief Financial Officer
Phone: (303) 381-6663
E-mail: Michael.Carruthers@arraybiopharma.com

Tricia Haugeto
Director, Corporate Communications and Investor Relations
Phone: (303) 386-1193
E-mail: Tricia.Haugeto@arraybiopharma.com

Transfer Agent
American Stock Transfer and Trust Company
6201 15th Avenue
Brooklyn, NY 11219
Phone: (800) 937-5449
Fax: (718) 236-4588
E-mail: Info@amstock.com
Website: http://www.amstock.com

Legal
Gross Cutler Seiler Dupont LLC
1877 Broadway, Suite 601
Boulder, CO 80302
Phone: (303) 926-4823

Accountants
KPMG LLP
707 Seventeenth Street, Suite 2700
Denver, CO 80202
Phone: (303) 295-5572


Replication or redistribution of EDGAR Online, Inc. content is expressly prohibited without the prior written consent of EDGAR Online, Inc. EDGAR Online, Inc. shall not be liable for any errors or delays in the content, or for any actions taken in reliance thereon.